Understanding the Efficacy of the Shingrix Vaccine

What is Shingrix?

Shingrix is a recombinant vaccine designed to prevent shingles, also known as herpes zoster. It uses a weakened form of the varicella-zoster virus (VZV), which causes chickenpox and later in life can reactivate as shingles.

Developed by GlaxoSmithKline, Shingrix is administered in two doses, typically six to twelve months apart, for optimal protection.

Efficacy of the Shingrix Vaccine

The vaccine has been shown to be highly effective in clinical trials. In studies, it demonstrated over 90% efficacy against shingles and postherpetic neuralgia (PHN) in adults aged 50 years or older.

Efficacy rates can vary slightly based on patient age and immune status, with younger individuals generally showing higher protection levels.

Factors Affecting Efficacy

Age plays a significant role in the efficacy of Shingrix. Older adults have been found to benefit more from the vaccine due to their increased risk of developing shingles and its complications.

Immune status also influences effectiveness, with individuals with compromised immune systems potentially requiring additional doses or alternative vaccines.

Real-World Impact

The widespread use of Shingrix has led to a significant reduction in the incidence of shingles and its associated complications, such as postherpetic neuralgia.

This vaccine is particularly important for individuals over 50 years old, who are at higher risk of developing shingles.

Frequently asked questions

Try it live

Everything above runs in your browser — open Shingrix Vaccine Efficacy Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.